SCHEMBL14488016

SCHEMBL14488016

CCCCCNS(=O)(=O)c1ccc(F)c(C(=O)Nc2ccc(F)c(F)c2)c1

nearest known ligand 0.58

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
LMNA P02545 13/20 0.58
MAPT P10636 12/20 0.58
RECQL P46063 1/20 0.58
POLB P06746 1/20 0.58
TP53 P04637 9/20 0.57
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
NPSR1 Q6W5P4 1/20 0.57
SMN1; SMN2 Q16637 3/20 0.55
HTT P42858 2/20 0.55
KDM4E B2RXH2 2/20 0.54
MAPK1 P28482 1/20 0.54
ALDH1A1 P00352 2/20 0.52
GAA P10253 1/20 0.49
THRB P10828 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17668340 0.97 LMNA (0.59) LMNAMAPTRECQLPOLBTP53
SCHEMBL15613050 0.92 MAPT (0.61) LMNAMAPTRECQLPOLBTP53
SCHEMBL17465684 0.86 LMNA (0.60) LMNAMAPTRECQLPOLBTP53
SCHEMBL17465683 0.86 MAPT (0.60) LMNAMAPTRECQLPOLBTP53
Hydrochloric Acid SCHEMBL15847781 0.85 LMNA (0.59) LMNAMAPTRECQLPOLBTP53
Hydrochloric Acid SCHEMBL15847850 0.85 MAPT (0.59) LMNAMAPTRECQLPOLBTP53
SCHEMBL15847613 0.84 LMNA (0.58) LMNAMAPTRECQLPOLBTP53
SCHEMBL15848305 0.83 MAPT (0.53) LMNAMAPTRECQLPOLBTP53
SCHEMBL20033697 0.82 LMNA (0.66) LMNAMAPTRECQLPOLBTP53
SCHEMBL19332177 0.82 POLB (0.60) LMNAMAPTRECQLPOLBTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2726459-A1 SULFAMOYLBENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION Institute for Hepatitis and Virus Research (US) 2014-05-07 EP claimed
WO-2013006394-A1 SULFAMOYLBENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION INSTITUTE FOR HEPATITIS AND VIRUS RESEARCH (US) 2013-01-10 WO claimed